Status:
COMPLETED
Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?
Lead Sponsor:
Kangdong Sacred Heart Hospital
Conditions:
Stomach Ulcer
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Treatment strategy of post endoscopic submucosal dissection (ESD) ulcer is not yet conclusive. Rebamipide is a mucosal protective agent widely used in East Asia and has good effect on quality of ulcer...
Eligibility Criteria
Inclusion
- patients underwent ESD for gastric adenoma or cancer
Exclusion
- subjects with previous gastric surgery
- subjects taking aspirin, anticoagulant, or antiplatelet agent
- subjects having malignancy except gastric cancer
- pregnant or breast-feeding women
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
290 Patients enrolled
Trial Details
Trial ID
NCT01167101
Start Date
May 1 2009
End Date
December 1 2010
Last Update
September 4 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kangdong Sacred Heart Hospital
Seoul, South Korea, 134-701